HUTCHMED (NASDAQ:HCM) Shares Gap Down – What’s Next?

HUTCHMED (China) Limited (NASDAQ:HCM)’s share price gapped down before the market opened on Monday . The stock had previously closed at $15.69, but opened at $15.03. HUTCHMED shares last traded at $15.05, with a volume of 17,368 shares.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Trading Down 3.6 %

The stock has a fifty day moving average of $14.67 and a two-hundred day moving average of $16.57. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC grew its holdings in HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock valued at $1,305,000 after purchasing an additional 49,366 shares during the last quarter. XY Capital Ltd acquired a new stake in HUTCHMED in the fourth quarter valued at $673,000. ABC Arbitrage SA acquired a new stake in HUTCHMED in the fourth quarter valued at $500,000. Renaissance Technologies LLC grew its holdings in HUTCHMED by 18.4% in the fourth quarter. Renaissance Technologies LLC now owns 188,539 shares of the company’s stock valued at $2,717,000 after purchasing an additional 29,239 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock valued at $952,000 after purchasing an additional 24,245 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.